<DOC>
	<DOCNO>NCT00051974</DOCNO>
	<brief_summary>The purpose study evaluate tumor patient non-small cell lung cancer respond treatment VELCADE alone versus VELCADE give docetaxel also see effect ( good bad ) cancer .</brief_summary>
	<brief_title>Phase 2 Study VELCADE Alone VELCADE® Plus Docetaxel Previously Treated Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>In study , patient non-small cell lung cancer longer respond standard medical treatment another anti-cancer drug randomly choose receive treatment VELCADE alone VELCADE combination docetaxel . Patients almost equal chance get either two treatment arm list .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria Inoperable , locally advanced ( Stage IIIB ) metastatic ( Stage IV ) NSCLC histologically cytologically confirm . No 1 prior chemotherapy regimen . 18 year age old . Measurable evaluable disease . KPS ≥70 % . Life expectancy great 3 month . Female patient either postmenopausal , surgically sterilize , willing use acceptable method birth control duration study . Male patient agree use acceptable method birth control duration study . Provide write informed consent studyrelated procedure part normal medical care conduct . Willing able comply protocol requirement . Exclusion Criteria Peripheral neuropathy Grade 2 great intensity , define NCI Common Toxicity Criteria ( CTC ) : Grade 2 : Objective sensory loss paresthesia ( include tingle ) , interfere function , interfere activity daily live ( ADLs ) . Grade 3 : Sensory loss paresthesia interfere ADLs . Grade 4 : Permanent sensory loss interfere function . Previous treatment VELCADE . Previous treatment docetaxel ( prior treatment paclitaxel allow ) . Chemotherapy within 4 week prior enrollment . Radiation therapy within 4 week prior enrollment . Monoclonal antibody within 6 week prior enrollment . Any major surgery within 4 week prior enrollment . Inadequate organ function Screening visit define follow laboratory value : Platelet count ≤100,000 x 109/L Hemoglobin ≤8.0 g/dL Absolute neutrophil count ( ANC ) ≤1.5 x 109/L Aspartate transaminase ( AST ) ≥3 x upper limit normal range ( ULN ) Alanine transaminase ( ALT ) ≥3 time ULN Creatinine ≥1.8 mg/dL Total bilirubin ≥2 time ULN Myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . No history brain metastases central nervous system disease . Active systemic infection require treatment . Treatment cancer NSCLC within 5 year prior enrollment , exception basal cell carcinoma cervical cancer situ . History allergic reaction attributable compound contain boron mannitol . Known human immunodeficiency virus ( HIV ) positive . Patients assess investigator risk HIV infection test accordance local regulation . Known hepatitis B surface antigenpositive know active hepatitis C infection . Patients assess investigator risk hepatitis B C infection test accordance local regulation . Poorly control hypertension , diabetes mellitus , another serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Pregnant breastfeed female patient . Confirmation patient pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain Screening period . Pregnancy test require postmenopausal surgically sterilize woman . Currently enrol another clinical research study receive investigational agent reason within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>